tiprankstipranks

ADC Therapeutics Announces $100M Private Placement

Story Highlights
  • ADC Therapeutics SA announced a $100 million private placement on June 11, 2025.
  • The company plans a restructuring, including a 30% workforce reduction, by September 30, 2025.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
ADC Therapeutics Announces $100M Private Placement

Elevate Your Investing Strategy:

ADC Therapeutics ( (ADCT) ) has issued an announcement.

On June 11, 2025, ADC Therapeutics SA announced a $100 million private placement with institutional investors, selling common shares and pre-funded warrants. This strategic move is aimed at bolstering their financial position and facilitating the company’s focus on expanding ZYNLONTA® and advancing its PSMA-targeting ADC. Concurrently, the company announced a restructuring plan to streamline operations by shutting down its U.K. research facility and reducing its workforce by 30%, with expected completion by September 30, 2025. This restructuring is anticipated to incur one-time pre-tax charges of approximately $6 million to $7 million.

The most recent analyst rating on (ADCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.

Spark’s Take on ADCT Stock

According to Spark, TipRanks’ AI Analyst, ADCT is a Neutral.

ADC Therapeutics’ overall stock score is primarily impacted by its weak financial performance and challenging valuation. While technical analysis shows bullish momentum, and corporate events and earnings call provide some positive insights, the company’s financial instability and negative profitability weigh heavily on the overall score.

To see Spark’s full report on ADCT stock, click here.

More about ADC Therapeutics

ADC Therapeutics SA operates in the biotechnology industry, focusing on the development of antibody-drug conjugates (ADCs) for the treatment of cancer. The company is particularly focused on expanding its ZYNLONTA® (loncastuximab tesirine-lpyl) product and advancing its preclinical exatecan-based ADC targeting prostate-specific membrane antigen (PSMA).

Average Trading Volume: 528,135

Technical Sentiment Signal: Buy

Current Market Cap: $364M

See more data about ADCT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1